Physician profile
Tyreasea A Johnson Mason
NPI 1003250101
$36,010.53
in general payments reported to CMS, 2019-2025
8 companies · $6,220 in 2025
The $6,220 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,242 · 2022: $3,795 · 2023: $8,004 · 2024: $11K · 2025: $6,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $5,201 · Honoraria: $4,225 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,600 · Food and Beverage: $546 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,375.00 |
| Consulting Fee | $5,200.50 |
| Honoraria | $4,225.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,600.00 |
| Food and Beverage | $545.69 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,483.63 | 2021-2025 | |
| Axsome Therapeutics, INC. | $12,167.21 | 2024-2025 | Auvelity |
| Allergan, INC. | $825.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.16 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $120.08 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $104.08 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $74.10 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyreasea Johnson Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.